首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?
【24h】

Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?

机译:B细胞前体急性淋巴细胞白血病中的免疫球蛋白重链基因座染色体易位:罕见的临床问题还是有效的遗传驱动因素?

获取原文
获取原文并翻译 | 示例
           

摘要

Chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus define common subgroups of B-cell lymphoma but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Recent fluorescent in situ hybridization and molecular cloning studies have identified several novel IGH translocations involving genes that play important roles in normal hemopoiesis, including the cytokine receptor genes CRLF2 and EPOR, all members of the CCAAT enhancer-binding protein gene family, as well as genes not normally expressed in hemopoietic cells including inhibitor of DNA binding 4. IGH translocation results in deregulated target gene expression because of juxtaposition with IGH transcriptional enhancers. However, many genes targeted by IGH translocations are also more commonly deregulated in BCP-ALL as a consequence of other genetic or epigenetic mechanisms. For example, interstitial genomic deletions also result in deregulated CRLF2 expression, whereas EPOR expression is deregulated as a consequence of the ETV6-RUNX1 fusion. The possible clinical importance of many of the various IGH translocations in BCP-ALL remains to be determined from prospective studies, but CRLF2 expression is associated with a poor prognosis. Despite their rarity, IGH chromosomal translocations in BCP-ALL therefore define not only new mechanisms of B-cell transformation but also clinically important subgroups of disease and suggest new targeted therapeutic approaches.
机译:涉及免疫球蛋白重链(IGH)基因座的染色体易位定义了B细胞淋巴瘤的常见亚组,但在B细胞前体急性淋巴细胞白血病(BCP-ALL)中很少见。最近的荧光原位杂交和分子克隆研究已经确定了几个新的IGH易位,这些基因涉及在正常造血中起重要作用的基因,包括细胞因子受体基因CRLF2和EPOR,CCAAT增强子结合蛋白基因家族的所有成员以及基因不能在造血细胞中正常表达,包括DNA结合抑制剂4。由于与IGH转录增强剂并置,IGH易位导致靶基因表达失控。然而,由于其他遗传或表观遗传机制,由IGH易位的许多基因在BCP-ALL中也更常被解除调控。例如,间质基因组缺失也导致CRLF2表达失调,而EPT6-RUNX1融合导致EPOR表达失调。 BCP-ALL中多种IGH易位的许多可能的临床重要性仍需通过前瞻性研究确定,但CRLF2表达与不良预后相关。尽管非常罕见,BCP-ALL中的IGH染色体易位因此不仅定义了B细胞转化的新机制,而且定义了疾病的临床重要亚组,并提出了新的靶向治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号